Serious adverse events 48 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes serious adverse events 48 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Non‐serious adverse events 43 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes non‐serious adverse events 43 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
1 finding from 1 review
SAEs · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people at increased risk for developing type 2 diabetes
Acarbose showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for the development of type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for the development of type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found